Get started
VYNE Therapeutics Inc.VYNE Therapeutics Inc.VYNE Therapeutics Inc.

VYNE Therapeutics Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VYNE chart


Full chart

VYNE upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪27.23 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.93 USD
Net income (FY)
‪−39.83 M‬ USD
Revenue (FY)
‪501.00 K‬ USD
Shares float
‪12.68 M‬
Beta (1Y)
1.05

Employees


Employees (FY)
13
Change (1Y)
+3 +30.00%
Revenue / Employee (1Y)
‪38.54 K‬ USD
Net income / Employee (1Y)
‪−3.06 M‬ USD

About VYNE Therapeutics Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David Domzalski
Website
vynetherapeutics.com
Headquarters
Bridgewater
Founded
2011
FIGI
BBG00H5W8GM8
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VYNE news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as VYNE.

Frequently Asked Questions


The current price of VYNE is 1.86 USD — it has increased by 0.56% in the past 24 hours. Watch VYNE Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange VYNE Therapeutics Inc. stocks are traded under the ticker VYNE.
VYNE stock has risen by 1.12% compared to the previous week, the month change is a 10.43% rise, over the last year VYNE Therapeutics Inc. has showed a −16.96% decrease.
We've gathered analysts' opinions on VYNE Therapeutics Inc. future price: according to them, VYNE price has a max estimate of 8.00 USD and a min estimate of 5.00 USD. Watch VYNE chart and read a more detailed VYNE Therapeutics Inc. stock forecast: see what analysts think of VYNE Therapeutics Inc. and suggest that you do with its stocks.
VYNE reached its all-time high on Feb 6, 2018 with the price of 2,869.92 USD, and its all-time low was 1.44 USD and was reached on Apr 7, 2025. View more price dynamics on VYNE chart.
See other stocks reaching their highest and lowest prices.
VYNE stock is 6.78% volatile and has beta coefficient of 1.05. Track VYNE Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is VYNE Therapeutics Inc. there?
Today VYNE Therapeutics Inc. has the market capitalization of ‪27.23 M‬, it has increased by 12.35% over the last week.
Yes, you can track VYNE Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
VYNE Therapeutics Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
VYNE earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.30 USD resulting in a 7.69% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about VYNE Therapeutics Inc. earnings.
VYNE Therapeutics Inc. revenue for the last quarter amounts to ‪84.00 K‬ USD, despite the estimated figure of ‪150.00 K‬ USD. In the next quarter, revenue is expected to reach ‪50.00 K‬ USD.
VYNE net income for the last quarter is ‪−12.02 M‬ USD, while the quarter before that showed ‪−12.16 M‬ USD of net income which accounts for 1.11% change. Track more VYNE Therapeutics Inc. financial stats to get the full picture.
No, VYNE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 13 employees. See our rating of the largest employees — is VYNE Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VYNE Therapeutics Inc. EBITDA is ‪−43.63 M‬ USD, and current EBITDA margin is ‪−8.71 K‬%. See more stats in VYNE Therapeutics Inc. financial statements.
Like other stocks, VYNE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VYNE Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VYNE Therapeutics Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VYNE Therapeutics Inc. stock shows the sell signal. See more of VYNE Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.